Antihistoplasmal in vitro and in vivo effect of Lys-Nva-FMDP

Medical Mycology

Volumn 36, Issue 3, 1998, Pages 177-180

  Milewski, S ^a   Mignini, F ^b   Micossi, L ^b   Borowski, E ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Antifungal agents; Chitin biosynthesis; Histoplasma; Lys Nva FMDP

Indexed keywords

ANTIFUNGAL AGENT; LEVO LYSYL LEVO NORVALYL N3 (4 METHOXYFUMAROYL) LEVO 2,3 DIAMINOPROPANOIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL WALL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG UPTAKE; ENZYME ACTIVITY; FUNGICIDAL ACTIVITY; GROWTH INHIBITION; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; MOUSE; NONHUMAN;

ANIMALS; ANTIFUNGAL AGENTS; BETA-ALANINE; BIOLOGICAL TRANSPORT; FEMALE; GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE (ISOMERIZING); HISTOPLASMA; HISTOPLASMOSIS; KINETICS; MEMBRANE TRANSPORT PROTEINS; MICE; SPLEEN;

EID: 0031852459     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-280X.1998.00133.x     Document Type: Article

References (18)

1. Emmons CW. Binford CB, Utz JP. Medical Mycology, 2nd edn. Philadelphia: Lea & Febiger, 1970: 301.
2. Medoff G. Maresca B. Lambowitz AM. Kobayashi GS, Painter A, Sacco M. Correlation between pathogenicity and temperature sensitivity in different strains of Histoplasma capsulatum. J Clin Invest 1986; 78: 1638-47.
3. Kobayashi GS, Travis SJ, Medoff G. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice. Antimicrob Agents Chemother 1987; 31: 2005-6.
4. Polak A, Hartman PG. Antifungal chemotherapy - are we winning? Prog Drug Res 1991; 37: 181-269.
5. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40: 279-91.
6. Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis and blastomycosis. Antimicrob Agents Chemother 1990; 34: 587-93.
7. Borowski E. 8th International Symposium on Future Trends in Chemotherapy, Tirrenia. Abstract Book, 1988: 158.
8. Milewski S, Chmara H, Andrusziewicz R. Borowski E, Zaremba M, Borowski J. Antifungal peptides with novel specific inhibitors of glucosamine-6-phosphate synthase. Drugs Exp Clin Res 1988; 14: 461-5.
9. Milewski S, Chmara H, Andruszkiewicz R, Zieniawa T, Borowski E. Rational design of FMDP-tripeptides, a new group of antifungal agents. Proceedings of the 16th International Congress of Chemotherapy, Jerusalem, Israel, 1989: 540 (1-2), 1989.
10. 3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid oligopeptides. J Med Chem 1990; 33: 132-5.
11. Mignini F, Falconi E, Carratu L, Pardini L, Kobayashi GS, Maresca B. Fluconazole influences the mycelium-to-yeast transition in the pathogenic fungus Histoplasma capsulatum. Med Microbiol Lett 1992; 1: 145-52.
12. Milewski S, Andruszkiewicz R, Kasprzak L, Mazerski J, Mignini F, Borowski E. Mechanism of action of anticandidal dipeptides containing inhibitors of glucosamine-6-phosphate synthase. Antimicrob Agents Chemother 1991; 35: 36-43.
13. Milewski S, Andruszkiewicz R, Borowski E. Substrate specificity of peptide permeases in Candida albicans. FEMS Microbiol Lett 1988; 50: 73-8.
14. Bollag DM, Edelstein SJ. Protein Methods. New York: WileyLiss, 1991: 37.
15. Doi E, Shibata D, Matoba T. Modified colorimetric ninhydrin method for peptidase assay. Anal Biochem 1981; 118: 173-84.
16. Kenig M, Vandamme E, Abraham EP. The mode of action of bacilysin and anticapsin and biochemical properties of bacilysinresistant mutants. J Gen Microbiol 1976; 94: 46-54.
17. 3-fumaroyl-L-2,3-diaminopropanoic acid inactivate glucosamine synthetase from Candida albicans. Biochem Biophys Acta 1985; 828: 247-54.
18. Domer JE. Monosaccharide and chitin content of cell walls of Histoplasma capsulatum and Blastomyces dermatitidis. J Bacteriol 1971; 107: 870-7.